Brokerages expect Crispr Therapeutics AG (NASDAQ:CRSP) to post earnings per share (EPS) of ($1.09) for the current fiscal quarter, Zacks Investment Research reports. Two analysts have issued estimates for Crispr Therapeutics’ earnings. The lowest EPS estimate is ($1.17) and the highest is ($0.96). Crispr Therapeutics reported earnings per share of ($0.93) during the same quarter last year, which indicates a negative year over year growth rate of 17.2%. The firm is scheduled to announce its next earnings results on Monday, May 4th.
On average, analysts expect that Crispr Therapeutics will report full-year earnings of ($4.54) per share for the current fiscal year, with EPS estimates ranging from ($5.22) to ($3.70). For the next fiscal year, analysts anticipate that the firm will post earnings of ($5.05) per share, with EPS estimates ranging from ($7.14) to ($3.78). Zacks Investment Research’s EPS calculations are an average based on a survey of research analysts that follow Crispr Therapeutics.
Crispr Therapeutics (NASDAQ:CRSP) last announced its earnings results on Wednesday, February 12th. The company reported $0.51 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.68) by $1.19. The business had revenue of $77.00 million during the quarter, compared to analysts’ expectations of $39.08 million. Crispr Therapeutics had a net margin of 23.09% and a return on equity of 11.74%. The firm’s revenue for the quarter was up 76900.0% on a year-over-year basis. During the same quarter last year, the company posted ($0.92) EPS.
Several research firms have weighed in on CRSP. ValuEngine upgraded shares of Crispr Therapeutics from a “sell” rating to a “hold” rating in a research report on Tuesday, March 3rd. Chardan Capital restated a “buy” rating and issued a $72.50 price objective on shares of Crispr Therapeutics in a research report on Thursday, February 13th. Piper Sandler restated a “buy” rating and issued a $104.00 price objective on shares of Crispr Therapeutics in a research report on Thursday, February 13th. Wells Fargo & Co reaffirmed a “buy” rating on shares of Crispr Therapeutics in a research note on Friday, December 6th. Finally, Stifel Nicolaus began coverage on shares of Crispr Therapeutics in a research note on Wednesday, March 4th. They issued a “hold” rating and a $52.00 target price on the stock. One analyst has rated the stock with a sell rating, four have assigned a hold rating and fourteen have assigned a buy rating to the company’s stock. Crispr Therapeutics has a consensus rating of “Buy” and a consensus price target of $72.25.
A number of institutional investors and hedge funds have recently made changes to their positions in the business. Nikko Asset Management Americas Inc. lifted its stake in Crispr Therapeutics by 9.8% in the fourth quarter. Nikko Asset Management Americas Inc. now owns 3,049,553 shares of the company’s stock valued at $185,733,000 after buying an additional 272,139 shares in the last quarter. ARK Investment Management LLC lifted its stake in Crispr Therapeutics by 6.3% in the fourth quarter. ARK Investment Management LLC now owns 2,956,635 shares of the company’s stock valued at $180,074,000 after buying an additional 174,495 shares in the last quarter. FMR LLC lifted its stake in Crispr Therapeutics by 71.8% in the fourth quarter. FMR LLC now owns 952,369 shares of the company’s stock valued at $58,004,000 after buying an additional 398,012 shares in the last quarter. Orbimed Advisors LLC bought a new position in Crispr Therapeutics in the third quarter valued at approximately $21,167,000. Finally, Franklin Resources Inc. lifted its stake in Crispr Therapeutics by 2.6% in the fourth quarter. Franklin Resources Inc. now owns 435,644 shares of the company’s stock valued at $26,533,000 after buying an additional 11,031 shares in the last quarter. 52.02% of the stock is currently owned by hedge funds and other institutional investors.
CRSP traded down $2.17 during midday trading on Wednesday, hitting $41.82. The company had a trading volume of 457,628 shares, compared to its average volume of 1,046,770. The company has a market capitalization of $2.68 billion, a PE ratio of 43.11 and a beta of 2.74. Crispr Therapeutics has a twelve month low of $32.30 and a twelve month high of $74.00. The firm’s 50-day simple moving average is $48.74 and its 200-day simple moving average is $52.90.
Crispr Therapeutics Company Profile
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells.
Recommended Story: What is an inverted yield curve?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.